Kuros Biosurgery
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Kuros Biosurgery sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).
Kuros Biosurgery: 4 sponsored US clinical trials, 3 recruiting.
Kuros Biosurgery sponsors 4 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 1 completed. The most-studied condition in this pipeline is Spine Fusion, with 2 trials.
Upper-quartile sponsor footprint
Kuros Biosurgery sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
4 total, page 1 of 1
A Prospective, Randomized, Single-blind, Controlled, Multi-center Study to Assess the Safety and Performance of MagnetOsTM Compared to Autogenous Bone Graft in Patients Undergoing Hindfoot or Ankle Fusions.
NCT07225751
Post Marketing Study of MagnetOs Easypack Putty Standalone Compared to Demineralized Bone Matrix or Fibers Mixed With Autograft in Patients Undergoing Posterolateral Lumbar Fusion
NCT04679844
MagnetOs Flex Matrix Compared to Trinity Elite Mixed With Local Autograft in Patients Undergoing up to Four-level Instrumented Posterolateral Fusion
NCT05037968
Post Marketing Study of MagnetOs Putty Compared to Local Autograft in Patients Undergoing Posterolateral Lumbar Fusion
NCT04679896
Therapeutic Areas
What is open in the Kuros Biosurgery pipeline
3 recruiting of 4 indexed (75% open); 1 completed (25%).
Phase labels are sparse on this sponsor index, so phase mix is not charted here.
Top condition: Spine Fusion (2 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Kuros Biosurgery: open-pipeline peers nationwide
Peers matched on 4 registered trials and 75% open enrollment, not the therapeutic-area sidebar.
Kuros Biosurgery sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 4 trials (± recruiting share)
- 4D pharma · 4 trials · 0% recruiting
- 60 Degrees Pharmaceuticals · 4 trials · 50% recruiting
- A2 Biotherapeutics · 4 trials · 75% recruiting
- Abdul Latif Jameel Poverty Action Lab · 4 trials · 25% recruiting
Sponsors near 75% open enrollment (± trial volume)
- Acepodia Biotech · 75% recruiting · 4 trials
- American Laboratory Products Company · 75% recruiting · 4 trials
- Amryt Pharma · 75% recruiting · 4 trials
- Amydis · 75% recruiting · 4 trials
Related
What to do with this Kuros Biosurgery page
4 registered trials is a research-attention snapshot, not an endorsement of Kuros Biosurgery or any single study.
- 3 of Kuros Biosurgery's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Spine Fusion is the condition Kuros Biosurgery studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Spine Fusion trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Kuros Biosurgery pipeline card: 4 registered trials from official public datasets.Report a data error.